Canada Infectious Disease Molecular Diagnostics Market Size & Outlook
The infectious disease molecular diagnostics market in Canada is expected to reach a projected revenue of US$ 715.2 million by 2030. A compound annual growth rate of 3% is expected of Canada infectious disease molecular diagnostics market from 2025 to 2030.
Clinical Diagnostics
In Vitro Diagnostics
Infectious Disease Molecular Diagnostics Market Outlook
The Canada infectious disease molecular diagnostics market generated a revenue of USD 597.9 million in 2024 and is expected to reach USD 715.2 million by 2030.
The Canada market is expected to grow at a CAGR of 3% from 2025 to 2030.
In terms of segment, reagents product was the largest revenue generating product in 2024.
Others Product is the most lucrative product segment registering the fastest growth during the forecast period.
Infectious disease molecular diagnostics market data book summary
Abbott Laboratories, Danaher Corp, BioMerieux SA, Roche Holding AG ADR, Bio-Rad Laboratories Inc, Agilent Technologies Inc, Becton Dickinson & Co, Hologic Inc, Illumina Inc, Grifols SA Ordinary Shares - Class A, Qiagen NV, Siemens Healthineers AG ADR, Sysmex Corp
Other key industry trends
In terms of revenue, Canada accounted for 3.8% of the global infectious disease molecular diagnostics market in 2024.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
In North America, U.S. infectious disease molecular diagnostics market is projected to lead the regional market in terms of revenue in 2030.
U.S. is the fastest growing regional market in North America and is projected to reach USD 7,175.8 million by 2030.
Canada is a rapidly developing market for infectious diseases molecular diagnostics. Incidence of infectious diseases is increasing at a rapid pace in the country, due to unhealthy lifestyle and low consumer awareness in some areas of the country.
Moreover, increase in hospital-acquired infections is expected to impel market growth. A significant number of cases of Methicillin-Resistant Staphylococcus Aureus (MRSA), Bloodstream Infections (BSIs) have been recorded in pediatric hospitals and Vancomycin-Resistant Enterococcus (VRE)- associated BSI in adult hospitals.
According to Public Health Agency of Canada in 2018, more than 20,000 hospital patients acquired antimicrobial-resistant infection each year. Use of molecular diagnostic devices has been increasing over the past few years, owing to rising prevalence of target diseases, such as Hospital-acquired Infections (HAIs) and HIV; rapid & early diagnosis leading to better treatment alternatives; and rise in health consciousness.
Canada Infectious Disease Molecular Diagnostics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Infectious Disease Molecular Diagnostics Market Outlook will help companies and investors design strategic landscapes.
Reagents Product was the largest segment with a revenue share of 67.67% in 2024.
Horizon Databook has segmented the Canada infectious disease molecular diagnostics market based on instruments product, reagents product, others product covering the revenue growth of each sub-segment from 2018 to 2030.
Canada is a rapidly developing market for infectious diseases molecular diagnostics. Incidence of infectious diseases is increasing at a rapid pace in the country, due to unhealthy lifestyle and low consumer awareness in some areas of the country.
Moreover, increase in hospital-acquired infections is expected to impel market growth. A significant number of cases of Methicillin-Resistant Staphylococcus Aureus (MRSA), Bloodstream Infections (BSIs) have been recorded in pediatric hospitals and Vancomycin-Resistant Enterococcus (VRE)- associated BSI in adult hospitals.
According to Public Health Agency of Canada in 2018, more than 20,000 hospital patients acquired antimicrobial-resistant infection each year. Use of molecular diagnostic devices has been increasing over the past few years, owing to rising prevalence of target diseases, such as Hospital-acquired Infections (HAIs) and HIV; rapid & early diagnosis leading to better treatment alternatives; and rise in health consciousness.
Canada Infectious Disease Molecular Diagnostics Market Product Outlook (Revenue, USD Million , 2018-2030)
Instruments Product
Reagents Product
Services Product
Canada Infectious Disease Molecular Diagnostics Market Test location Outlook (Revenue, USD Million , 2018-2030)
Hospitals
Clinics
Diagnostics Laboratories
Research Institutes
Canada Infectious Disease Molecular Diagnostics Market Technology Outlook (Revenue, USD Million , 2018-2030)
Canada Infectious Disease Molecular Diagnostics Market Application Outlook (Revenue, USD Million , 2018-2030)
Respiratory Diseases
Tuberculosis
Meningitis
Gastrointestinal Tract Infections
HPV
Sexually Transmitted Infection
Sepsis
Drug Resistance Disease
Others Application
Reasons to subscribe to Infectious Disease Molecular Diagnostics Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Infectious Disease Molecular Diagnostics Market Outlook databook
Our clientele includes a mix of Infectious Disease Molecular Diagnostics Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada Infectious Disease Molecular Diagnostics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Canada Infectious Disease Molecular Diagnostics Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.